TherapeuticsMD (NASDAQ:TXMD) Stock Crosses Below 50-Day Moving Average – Should You Sell?

TherapeuticsMD, Inc. (NASDAQ:TXMD) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.05 and traded as low as $2.03. TherapeuticsMD shares last traded at $2.03, with a volume of 14,096 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TherapeuticsMD in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, TherapeuticsMD has an average rating of “Sell”.

TherapeuticsMD Price Performance

The stock has a market capitalization of $23.49 million, a P/E ratio of 33.83 and a beta of 0.59. The company has a fifty day moving average of $2.05 and a two-hundred day moving average of $2.15.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Tuesday, May 12th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($6.12) by $6.13. The company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $19.77 million. TherapeuticsMD had a return on equity of 0.32% and a net margin of 5.34%.

Hedge Funds Weigh In On TherapeuticsMD

Several large investors have recently added to or reduced their stakes in the company. Tejara Capital Ltd increased its stake in TherapeuticsMD by 1.9% during the fourth quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after purchasing an additional 6,649 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of TherapeuticsMD by 51.5% during the first quarter. Renaissance Technologies LLC now owns 146,200 shares of the company’s stock worth $295,000 after purchasing an additional 49,700 shares during the period. Finally, Citadel Advisors LLC lifted its position in shares of TherapeuticsMD by 125.5% in the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock worth $36,000 after buying an additional 19,073 shares during the last quarter. 30.74% of the stock is currently owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.